Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)

Trial Profile

Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Rabeprazole (Primary) ; Famotidine
  • Indications Peptic ulcer
  • Focus Therapeutic Use
  • Acronyms ASP(PPI-H2RA)
  • Most Recent Events

    • 20 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 15 Sep 2016 Results published in the Gastroenterology.
    • 11 Sep 2016 Primary endpoint (Recurrent non-variceal upper GI bleeding) has not been met, according to results published in the Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top